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In clinically organ-confined prostate cancer patients, bloodstream tumour cell dissemination generally occurs, and may be enhanced
by surgical prostate manipulation. To evaluate cancer-cell seeding impact upon patient recurrence-free survival, 155 patients were
prospectively enrolled then followed. Here, 57 patients presented blood prostate cell shedding preoperatively and intraoperatively
(group I). Of the 98 preoperatively negative patients, 53 (54%) remained negative (group II) and 45 (46%) became intraoperatively
positive (group III). Median biological and clinical recurrence-free time was far shorter in group I (36.2 months, Po0.0001) than in
group II (69.6 months) but did not significantly differ in group II and III (69.6 months vs 65.0). Such 5-year follow-up data show that
preoperative circulating prostate cells are an independent prognosis factor of recurrence. Moreover, tumour handling induces cancer-
cell seeding but surgical blood dissemination does not accelerate cancer evolution.
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In cancer surgery, local and distant recurrences may be explained
by incomplete resection, leaving behind residual cancer cells in the
resected stump area, and/or presence of undetectable regional
micrometastases. Highly frequent detection of tumour-surround-
ing tissue-derived cells in the bloodstream during surgical tumour
handling has often been reported in case of liver, colon, breast,
gastric, and lung adenocarcinomas (Wong et al, 1999; Yamashita
et al, 2000). Likewise, our previous study focusing on a potential
risk for haematogenous spillage of prostate cancer cells during
tumour handling has evidenced a 30–80% rise in the rate of
circulating peripheral prostatic cells at the time of radical
prostatectomy procedure during which the prostatic blood flows
straight into the systemic circulation without any possibility of
pedicle ligation (Eschwege et al, 1995). Among these circulating
prostate cells, the presence of cancer cells with capabilities to
further develop metastatic foci cannot be ruled out (Cristofanilli
et al, 2004). Hence, additionally to the spontaneous prostate cell
spillage inherent to the natural history of cancer, a mechanical
spillage may occur during surgery. An unresolved issue, that seems
important to surgeons, remains to know whether surgical
manipulation of malignant tumours could promote haematogen-
ous spread of tumour cells and further increase the incidence of
distant metastasis. Thus, the aims of our prospective study were:
(i) to assess the use of preoperative prostate cell detection as a
prognosis marker of prostate cancer biological recurrence, and (ii)
to elucidate whether tumour manipulation during retropubic
radical prostatectomy (RP) may accelerate cancer dissemination.
MATERIALS AND METHODS
We enrolled prospectively 176 consecutive men presenting biopsy-
established prostate adenocarcinoma clinically confined to the
prostate gland according to standard criteria and undergoing RP.
None of them received hormonal therapy before surgery. Among
this group, 21 were lost and only 155 patients were analysed.
Clinical and pathological staging was performed using the TNM92
system, and patient stages were either pT2N0M0 or pT3N0M0
(casuistic is summarised in Table 1). Informed consent was
obtained from each patient, and the study was approved by the
ethical committee of our institution. Two 7ml antecubital venous
blood samples (EDTA-containing vacutainers, Beckton Dickinson,
Le Pont de Claix, France) were drawn preoperatively 1 day before
RP (referred to as preoperative sample) and, during surgery, 5min
after prostate removal (intraoperative sample). Haematogenous
spread of prostate cells was assessed by a dual PSA/PSMA
RT–PCR assay using very specific PSMA primers (forward
PSMAF: gaatgccagagggcgatcta; reverse PSMAR: ttctgtgcatcatagta
tcc; nested forward PSMANF: ggagtcattctctactccga; nested reverse
PSMANR: ctctgcaattccacgcctat) and PSA (PSAF: tgcgcaagttcacc
ctca; PSAR: ccctctccttacttcatcc; PSANF: ctgtgtgctggacgcttg; PSANR:
acctcacacctaaggaca) and considered positive when both markers
were found to be expressed. Briefly, after RNA extraction and
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sreverse transcription into cDNA as previously described
(Eschwege et al, 1995; Tombal et al, 2003), a first row of PCR was
performed using outer couples of PSA (PSAF, PSAR) and PSMA
(PSMAF, PSMAR) primers in a multiplex fashion on 10ml cDNA
(25 PCR cycles with 1min hybridisation at 601C at each cycle).
After the first amplification was done, 1ml of the amplification
product was poured into two distinct tubes to perform nested PCR
using inner couples of primers (PSMANF, PSMANR in the PSMA
tube, PSANF, PSANR in the PSA tube) for 25 additional cycles with
1min hybridisation at 601C at each cycle. As each forward primer
was labelled at 50-terminus by 6-FAM, fluorescent PCR products
were analysed using Genescan technology on a 3100 genetic
analyser (Applied Biosystems, Les Ulis, France). Robustness of the
method was tested using LNCaP prostate cell line spiking
experiments in normal blood. Limit of detection was found very
low, detecting as few one prostate cell in 1ml blood. Accuracy was
also checked with intra- and inter-assay coefficients of variation of
8.9 and 10.5% respectively. No false positivity was observed in
more than 100 healthy individuals who were tested as controls
confirming the specificity of the method. Biochemical progression
was defined as two consecutive serum PSA values of 0.2ngml
 1 or
greater (Elecsys2010, Roche, Meylan, France). To determine if
RT–PCR results correlated with progression-free survival, a Cox
regression was performed, and included preoperative PSA, Gleason
score, pathological stage and RT–PCR results. The recurrence-free
results were also assessed by the product-limit method of Kaplan–
Meier. Comparisons between groups were performed by the log-
rank method (SPSS10
s and Prism4
s statistical softwares).
RESULTS
Blood dissemination of prostatic cells was preoperatively present
in 57 patients (37%) (Group I) and absent in the 98 remaining
patients (63%). Of these 98 preoperatively negative patients 45
(46%) became intraoperatively positive. Thus, regarding surgically
induced blood prostatic cell shedding, two groups of patients can
be differentiated: group II including preoperatively negative/
intraoperatively negative (n¼53) and group III preoperatively
negative/intraoperatively positive patients (n¼45). Although
some of the clinical/biological factors remained relevant in the
multivariate analysis (preoperative serum PSA, pathological stage,
both Po0.01), the preoperative positivity of circulating
prostate cells emerged as the strongest predictor of progression-
free survival (Po0.001). The median biological and clinical
recurrence-free time was two times as short for group I
preoperatively positive patients as for groups II and III preopera-
tively negative patients (36.2 months, log-rank w
2¼16.02,
Po0.0001) (Figure 1A) thus showing that preoperative haemato-
genous spillage of prostate cells is adversely affecting prostate
cancer patient survival. In contrast, the median recurrence-free time
was not significantly different in group II when compared to group
III (69.6 months and 65.0 months, respectively; log-rank, w
2¼0.053,
P¼0.818, NS) (Figure 1B), revealing thereby that surgically induced
prostate cell seeding in blood does not accelerate cancer evolution.
DISCUSSION
Refinements in surgical treatments have reduced surgical mortality
in patients with solid epithelial tumours. The fate of cancer
patients is generally linked to early tumour cell dissemination
initially undetectable by conventional means (Cristofanilli et al,
2004). Blood-borne cancer cell detection arises as one of the recent
methods to evaluate such seeding before any treatment. Our results
unambiguously show the existing link between haematogenous
spread of prostate cells, cancer recurrence and prognosis.
Although, in our hand, PSA/PSMA transcripts specific RT–PCR
quantification does not increase patient staging accuracy (data not
shown), qualitative CPC detection (Yes/No answer on the basis of
the presence of specific prostate transcripts in blood) appears to be
sufficient to classify patients into two groups. The first one features
patients with positive preoperative CPC detection (Group I) and a
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Figure 1 Progression-free survival for the three groups of patients. (A)
Kaplan–Meier estimates of probabilities of progression-free survival.
Patients with no preoperative circulating prostatic cells (Neg PreOp
CPC) and with preoperative circulating prostatic cells (Pos PreOp CPC)
are compared, Po0.0001 by the log-rank test, w
2¼16.02. (B) Kaplan–
Meier estimates of probabilities of progression-free survival. Patient without
preoperative circulating prostatic cells and with (Neg PreOp, Pos IntraOp
CPC) or without (Neg PreOp, Neg IntraOp CPC) intraoperative prostatic
circulating cells are compared, P¼0.818, NS by the log-rank test,
w
2¼0.053.
Table 1 Clinical data for the three groups of patients
Group I Group II Group III
Preoperative prostatic cell shedding Yes No No
Intraoperative prostatic cell shedding Yes No Yes
n 57 53 45
Age years (s.d.) 64.3 (4.2) 63.5 (5.1) 65.0 (4.9)
PSA ngml
 1 (s.d.) 10.9 (6.02) 9.29 (5.3) 10.5 (6.09)
Positive surgical margin 11 12 10
pTNM/UICC classification:
pT2 N0 M0 23 22 14
pT3 N0 M0 18 16 18
Gleason score (s.d.) 6.78 (1.12) 6.39 (1.33) 6.58 (0.92)
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shigh probability of recurrence. The second one comprises patients
with negative preoperative CPC detection (Group IIþIII) and a
low probability of recurrence (Figure 1A). These data regarding
clinically localised CaP patients complete the results of Moreno
et al (2005) and more recently those of Okegawa et al (2008) that
have shown correlation between CPC number and prostate cancer
mortality in metastatic patients. Thus, as preoperative CPC
detection or numeration seems a major indicator of primitive
prostate tumour aggressiveness, it could be added to initial patient
staging, to further propose a better treatment (either surgical or
non-surgical).
Nevertheless, surgical cure requires that the tumour should be
removed without inadvertent spillage of cancer cells at the time of
organ handling and surgical manipulations. It is now well
established that surgical variations do exist together with
measurable rates of both local recurrence and survival (Birbeck
et al, 2002). Patients who have persistently positive blood samples
after radical surgery may be those at risk for systemic relapse but
additional studies have also shown that most circulating tumour
cells do not survive, with as little as 0.1% being responsible for the
formation of secondary foci (Mareel et al, 1993).
Preliminary investigations with small numbers of samples have
suggested that intraoperative tumour manipulations at surgery for
primary breast, colorectal, and prostatic cancers induce tumour cell
dissemination (Weitz et al, 1998; Weitz and Herfarth, 2001; Lintula
et al, 2004). Nevertheless, in the absence of longer term follow-up,
these studies failed to provide evidence that this cell dissemination
may cause secondary metastatic deposits and affect survival.
Concern about dislodging of tumour emboli during carcinoma
resection encouraged the introduction of the no-touch technique
wherever primary lymphovascular pedicle ligation was possible.
This surgical procedure was first assessed in colorectal carcinoma
and, using molecular cell detection in a small subset of colorectal
cancer patients, we evaluated the no-touch technique impact in
colorectal surgery on intraoperative tumour cell dissemination
(Sales et al, 1999). Nevertheless, in the only available prospective,
randomised trial evaluating colorectal cancer patients, Wiggers
et al (1988) failed to evidence any statistically significant impact of
the no-touch technique on 5-year survival and suggested that
surgically induced tumour cell dissemination did not affect
prognosis. This is the reason why we were prompted to design a
prospective study to evaluate prostate cancer cell dissemination at
the time of radical prostatectomy procedure, which offers no
opportunity to use the no-touch technique due to anatomic
characteristics. For patients who did not undergo preoperative
prostate cell dissemination, our 5-year follow-up results show no
statistically significant differences between the absolute 5-year
recurrence-free rates in intraoperative negative (group II) and
intraoperative positive (group III) for prostatic cell shedding.
Thus, we do evidence blood prostate cell spillage during surgical
manipulation (45 patients among the 98 preoperatively negative
were found positive intraoperatively). However, as no higher
recurrence rate was observed in group III (intraoperatively
positive) than in group II (intraoperatively negative), this surgical
cell dissemination does not have any statistical consequences on
the prognosis of these two preoperatively negative groups (II and
III) (Figure 1B). Then, when we aggregate the comparative results
for the three groups, it seems that the pejorative aspect of the
prostate cell dissemination is a consequence of intrinsic cell
characteristics (group I), and not a consequence of the surgical
mechanical spreading of prostate cells where most of the cells are
not yet competent to determine metastasis emergence (group III).
In radical surgery for prostate adenocarcinoma, haematogenous
prostate cell spillage frequently occurs (i) preoperatively and (ii)
during manipulation of the tumour. The preoperative blood
spillage of prostatic cells show a strong biological recurrence
predictive power, which is independent of other classical markers
such as blood PSA initial levels. Thus, preoperative circulating
prostate cells detection can be used as an additional marker to
better stadify patients. Prostate cell blood dissemination was also
detected intraoperatively, nevertheless, such spillage has not been
shown to have any statistically significant adverse effect on
recurrence, which seems to exclude tumour surgical management
as a major cause of metastatic development. Our results suggest
that intrinsic factors linked to the tumour itself mainly contribute
to cancer evolution and subsequent poorer prognosis.
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